Committee Decisions

This drug has not yet been assessed for formulary status.
It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

NICE are due to publish guidance on this drug (date tbc) and this will be considered by the APC within 90 days of publication.

This drug has not yet been assessed for formulary status.
It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

NICE are due to publish guidance on this drug (date tbc) and this will be considered by the APC within 90 days of publication.

INTESTINAL GEL:

This drug falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.

Clinicians / specialists within the Acute setting should only prescribe in line with their Trust formulary / pharmacy advice.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

This drug has not yet been assessed for formulary status [for this indication] and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

This drug / formulation has not yet been assessed for formulary status and is not currently on the APC work-plan.

This formulation has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

This drug has not yet been assessed for formulary status for endometriosis and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

This drug has not yet been assessed for formulary status for COPD.
It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing this drug it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

NICE are due to publish guidance on this drug (publication date to be confirmed) and this will be considered by the APC within 90 days of publication.

This drug/device has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug/device has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. 

Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

This drug has not yet been assessed for formulary status for the prevention of cardiovascular events.

It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. 
Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

NICE have not yet carried out an appraisal but, once published, it will be considered by the APC within 90 days.

The Medicines Resource Unit (MRU) is the clinical coordination hub for Medicines Management. The MRU provide the mechanisms to support the safe and cost effective management of medicines across all partner organisations in Surrey Heartlands.

The teams writes the majority of the papers for the Area Prescribing Committee and if you want to get involved and would like to work with us to write a paper for the APC then please do get in touch by contacting us at syheartlandsicb.apc@nhs.net 

This drug has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsccg.APC@nhs.net  if they wish to make a submission.
 

Surrey contraceptive guidelines can be found here: https://surreyccg.res-systems.net/PAD/Guidelines/Detail/6303

This drug falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.

Clinicians / specialists within the Acute setting should only prescribe in line with their Trust formulary / pharmacy advice.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

This drug falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.

Clinicians / specialists within the Acute setting should only prescribe in line with their Trust formulary / pharmacy advice.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

Excluding palliative care.

Tablets 6.25mg and Oral solution 5mg/ml

This drug has not yet been assessed for formulary status [for 2nd/3rd line refractory nausea and vomiting] and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

Levomepromazine oral solution 5mg/ml

This drug has not yet been assessed for formulary status [for this indication] and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

Levomepromazine tablets 6.25mg

This drug has not yet been assessed for formulary status [for this indication] and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

This device has not yet been assessed for formulary status and is not currently on the APC work-plan.

This device has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

This drug has not yet been assessed for formulary status [for this indication] and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

This device has not yet been assessed for formulary status and is not currently on the APC work-plan.

This device has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

Mizolastine has been discontinued - Apr 2024.

Please refer to the local hay fever guidelines for alternatives

This drug has not yet been assessed for formulary status [for this indication] and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

Note: this is a "P" medicine that is available to purchase from a pharmacy.

This drug falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.

Clinicians / specialists within the Acute setting should only prescribe in line with their Trust formulary / pharmacy advice.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

This drug falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.

Clinicians / specialists within the Acute setting should only prescribe in line with their Trust formulary / pharmacy advice.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

This drug has not yet been assessed for formulary status.
It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing this drug it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

NICE are due to publish guidance later this year and will be considered by the APC within 90 days. Date of NICE publication to be confirmed. 

This drug falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.

Clinicians / specialists within the Acute setting should only prescribe in line with their Trust formulary / pharmacy advice.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

This drug/device has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug/device has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

This drug/device has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug/device has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

This drug falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.

Clinicians / specialists within the Acute setting should only prescribe in line with their Trust formulary / pharmacy advice.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

This drug falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.

Clinicians / specialists within the Acute setting should only prescribe in line with their Trust formulary / pharmacy advice.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

This drug has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

This drug has not yet been assessed for formulary status [for this indication].
It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing this drug it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

NICE are due to publish guidance on this drug (date to be confirmed) and this will be considered by the APC within 90 days of publication.

This drug/device has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug/device has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

This drug/device has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug/device has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.

Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

From the 1st February 2024, patients eligible for treatment with Covid antiviral medicines will be able to obtain a supply from one of our locally designated Community Pharmacies.

Prescriptions will be sent via the Electronic Prescription Service (EPS) to one of the designated pharmacies.

A list of these pharmacies can be found in the document "CMDU Community Pharmacies from Feb 2024"

From the 1st February 2024, patients eligible for Covid treatment will be able to obtain a supply from one of our locally designated Community Pharmacies.

Prescriptions will be sent via the Electronic Prescription Service (EPS) to one of the designated pharmacies.

A list of these pharmacies can be found in the document "CMDU Community Pharmacies from Feb 2024"

From the 1st February 2024, patients eligible for treatment with Covid antiviral medicines will be able to obtain a supply from one of our locally designated Community Pharmacies.

Prescriptions will be sent via the Electronic Prescription Service (EPS) to one of the designated pharmacies.

A list of these pharmacies can be found in the document "CMDU Community Pharmacies from Feb 2024"

This drug has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

This drug has not yet been assessed for formulary status.
It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing .

NICE have not yet provided a publication date but this drug will be considered by the APC within 90 days of NICE publication

This drug has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

This drug falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.

Clinicians / specialists within the Acute setting should only prescribe in line with their Trust formulary / pharmacy advice.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication

This drug has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

This drug has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

This drug has not yet been assessed for formulary status.
It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.

NICE are expected to publish guidance on this drug (date tbc) and this will be considered by the APC within 90 days of publication

This drug has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

The use of High Dose Inhaled Corticosteroid (ICS) Safety Cards are recommended where appropriate. Patients on very high doses should also be issued with a Steroid Emergency Card. Refer to the Steroid Card resources for guidance.

This drug falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.

Clinicians / specialists within the Acute setting should only prescribe in line with their Trust formulary / pharmacy advice.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication

This drug falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.

Clinicians / specialists within the Acute setting should only prescribe in line with their Trust formulary / pharmacy advice.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication

This drug falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.

Clinicians / specialists within the Acute setting should only prescribe in line with their Trust formulary / pharmacy advice.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication

This drug is likely to fall under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.

NICE is expected to publish guidance in April 2024.
 

This drug / device has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug / device has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug / device.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.

This drug / device has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug / device has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug / device.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.
 

This drug / device has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug / device has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug / device.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.
 

This drug / device has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug / device has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug / device.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.
 

This drug / device has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.
 

This device has not yet been assessed for formulary status and is not currently on the APC work-plan.

This device has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.
 

This drug has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net  if they wish to make a submission.
 

This drug has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsccg.APC@nhs.net  if they wish to make a submission.
 

This drug has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsccg.APC@nhs.net  if they wish to make a submission.
 

This product has not yet been assessed for formulary status and is not currently on the APC work-plan.

This product has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsccg.APC@nhs.net  if they wish to make a submission.
 

This drug has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsccg.APC@nhs.net  if they wish to make a submission.
 

Surrey contraceptive guidelines can be found here: https://surreyccg.res-systems.net/PAD/Guidelines/Detail/6303

This drug / device has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsccg.APC@nhs.net  if they wish to make a submission.
 

This drug has not yet been assessed for formulary status.
It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.

NICE are due to publish guidance on this drug in Jul 2023 and this will be considered by the APC within 90 days of publication

This drug has not yet been assessed for formulary status.
It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.

NICE are due to publish guidance on this drug in Apr 2023 and this will be considered by the APC within 90 days of publication

GREEN/BLACK - Not for new initiation: Initiation of this drug is NOT recommended in any health care setting across Surrey Heartlands Integrated Care System. Prescribers can, however, continue to prescribe for patients already taking this drug.

1. The drug has been evaluated as no longer being a preferred treatment option for this condition
2. There is no expectation for existing, stable patients to change drug or device unless this is agreed as an appropriate course of action
3. Consider discontinuation when a change in the patient’s condition requires medication review.

RED - Spcialist only drugs, initiated and continued by specialist clinicians

• Specialist assessment to enable patient selection, initiation and continuation of treatment
• Long term specialist monitoring of efficacy and not suitable for shared care
• Long-term, on-going specialist monitoring of toxicity (because the side-effect profile necessitates rigorous supervision by the hospital consultant or, the full range of possible side-effects, particularly long-term effects needs to be established; or problematic investigations to identify toxicity)
• Specifically designated as being “specialist” or “hospital only” by product license, Department of Health, NICE
   

Amber - Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement

Blue - Prescribing initiated and stabilised by a specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care

Non-formulary (previously Black) - not recommended

1. Lack of evidence of benefit compared with standard
2. Lack of evidence of safety compared with standard
3. Less cost-effective than standard therapy
4. NICE guidance does not recommend

The Discharge Medicines Service (formerly known as Transfer of Care Around Medicines TCAM) is an Essential Service provided by Community Pharmacy.

The service aims to facilitate the seamless transfer of medicines information at the point of discharge from hospitals to the patient's choice of Community Pharmacy.

A Community Pharmacy Referral Pathway has been developed using an IT system called PharmOutcomes.

For further local and national information please see the links below

This drug/device has not yet been assessed for formulary status. but is on the APC work-plan.

This drug/device has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC).  As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug / device.

This advice will be updated after consideration by the APC.

This drug / device should be used in conjunction with photodynamic therapy (PDT) and therefore should not be prescribed in Primary Care.

Clinicians / specialists within the Acute setting should only prescribe in line with their Trust formulary / pharmacy advice.

This drug / device has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsccg.APC@nhs.net  if they wish to make a submission.

Refer to local acne guidelines: https://surreyccg.res-systems.net/PAD/Guidelines/Detail/6307

This drug / device has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsccg.APC@nhs.net  if they wish to make a submission.
 

This device has not yet been assessed for formulary status and is not currently on the APC work-plan.

This device has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug / device.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsccg.APC@nhs.net  if they wish to make a submission.
 

This device has not yet been assessed for formulary status and is not currently on the APC work-plan.

This device has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug / device.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsccg.APC@nhs.net  if they wish to make a submission.

Primary care prescribers are not expected to have the clinical expertise to prescribe these devices and should therefore not be asked to prescribe until a formal evaluation and recommendations have been submitted to the APC.

This drug / device has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsccg.APC@nhs.net  if they wish to make a submission. 
 

This drug has not yet been assessed for formulary status and is not currently on the APC work-plan.

This drug has not yet been evaluated by the Surrey Heartlands Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.
The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsccg.APC@nhs.net  if they wish to make a submission. 
 

The Royal College of Ophthalmologists issued guidelines which recommend that all patients planning to take hydroxychloroquine long term i.e. over five years have a baseline examination in a hospital eye department ideally within six months, but definitely within 12 months. Patients should be referred for annual screening after five years of therapy and be reviewed annually thereafter whilst on therapy.

East Surrey Place: see narrative below from Feb 2020

Guildford & Waverley Place: A retinopathy screening service is provided by Frimley Health NHS Foundation Trust. A self-populating referral form is available on EMIS.

North West Surrey Place: A retinopathy screening service is provided by Frimley Health NHS Foundation Trust. A self-populating referral form is available on EMIS.

Guidelines from the Royal College of Ophthalmologists: Hydroxychloroquine-and-Chloroquine-Retinopathy-Monitoring-Guideline.pdf (rcophth.ac.uk)

The Royal College of Ophthalmologists issued guidelines which recommend that all patients planning to take hydroxychloroquine long term i.e. over five years have a baseline examination in a hospital eye department ideally within six months, but definitely within 12 months. Patients should be referred for annual screening after five years of therapy and be reviewed annually thereafter whilst on therapy.

East Surrey Place: see narrative below from Feb 2020

Guildford & Waverley Place: A retinopathy screening service is provided by Frimley Health NHS Foundation Trust. A self-populating referral form is available on EMIS.

North West Surrey Place: A retinopathy screening service is provided by Frimley Health NHS Foundation Trust. A self-populating referral form is available on EMIS.

Guidelines from the Royal College of Ophthalmologists: Hydroxychloroquine-and-Chloroquine-Retinopathy-Monitoring-Guideline.pdf (rcophth.ac.uk)

These drugs falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.

Clinicians / specialists within the Acute setting should only prescribe in line with their Trust formulary / pharmacy advice.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication

This drug is currently not on the APC workplan. The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Please contact your local CCG Medicines Management team OR formulary pharmacist at your acute trust, if you wish to make a submission. This drug is currently not on the APC workplan. The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Please contact your local CCG Medicines Management team OR formulary pharmacist at your acute trust, if you wish to make a submission. 

This drug is currently not on the APC workplan. The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Please contact your local CCG Medicines Management team OR formulary pharmacist at your acute trust, if you wish to make a submission

This drug is currently not on the APC workplan. The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Please contact your local CCG Medicines Management team OR formulary pharmacist at your acute trust, if you wish to make a submission. 
This drug has not yet been evaluated by NICE or the Surrey and North West Sussex Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.

This drug is currently not on the APC workplan. The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Please contact your local CCG Medicines Management team OR formulary pharmacist at your acute trust, if you wish to make a submission. 
This drug has not yet been evaluated by NICE or the Surrey and North West Sussex Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.

This drug falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.
Treatment should remain with the specialist (RED) hospital only drug.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

This drug / device falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care

Treatment should remain with the specialist (RED) hospital only drug.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication

The Medicines Safety Matters bulletins aim to promote a culture for improved medicines safety across Surrey Heartlands.

The bulletins contain information about local and national safety incidents and the learning from them.

Further guidance and a list of the latest safety alerts can be found here:

https://surreyccg.res-systems.net/PAD/Guidelines/Detail/4992

The following documents support healthcare professionals (HCPs) in primary care to advise on or seek further advice on drugs in pregnancy

This drug is on the APC workplan, but it has not yet been evaluated by NICE or the Surrey & North West Sussex Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined

This drug falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care

This drug is currently not on the APC workplan. The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Please contact your local CCG Medicines Management team formulary pharmacist or chief pharmacist at your acute trust, if you wish to make a submission.

This drug has not yet been evaluated by NICE or the Surrey and North West Sussex Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug / device.

The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Please contact your local CCG Medicines Management team formulary pharmacist or chief pharmacist at your acute trust, if you wish to make a submission.

This drug / device falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care. 
Treatment should remain with the specialist (RED) hospital only drug. 

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication

This drug has not yet been evaluated by NICE or the Surrey and Sussex Prescribing Clinical Network (PCN) for use in alopecia. As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. 

This drug is currently not on the PCN workplan. The PCN will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Please contact your local CCG Medicines Management team formulary pharmacist or chief pharmacist at your acute trust, if you wish to make a submission.

If asked to prescribe, please contact a member of your Medicines Management Team

This drug has not yet been evaluated by NICE or the Surrey and Sussex Prescribing Clinical Network (PCN) for use in alopecia. As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. 

This drug is currently not on the PCN workplan. The PCN will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Please contact your local CCG Medicines Management team formulary pharmacist or chief pharmacist at your acute trust, if you wish to make a submission.

If asked to prescribe, please contact a member of your Medicines Management Team

This drug has not yet been evaluated by the Surrey and Sussex Prescribing Clinical Network (PCN). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. 

This drug is currently not on the PCN workplan. The PCN will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Please contact your local CCG Medicines Management team formulary pharmacist or chief pharmacist at your acute trust, if you wish to make a submission.

If asked to prescribe, please contact a member of your Medicines Management Team

This drug has not yet been evaluated by the Surrey and Sussex Prescribing Clinical Network (PCN). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. 

This drug is currently not on the PCN workplan. The PCN will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Please contact your local CCG Medicines Management team formulary pharmacist or chief pharmacist at your acute trust, if you wish to make a submission.

If asked to prescribe, please contact a member of your Medicines Management Team

This drug has not yet been evaluated by the Surrey and Sussex Prescribing Clinical Network (PCN). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. 

This drug is currently not on the PCN workplan. The PCN will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Please contact your local CCG Medicines Management team formulary pharmacist or chief pharmacist at your acute trust, if you wish to make a submission.

If asked to prescribe, please contact a member of your Medicines Management Team

This drug / device falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care. Treatment should remain with the specialist (RED) hospital only drug. GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

These drugs falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.

Clinicians / specialists within the Acute setting should only prescribe in line with their Trust formulary / pharmacy advice.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication

These drugs falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.

Clinicians / specialists within the Acute setting should only prescribe in line with their Trust formulary / pharmacy advice.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication

This drug / device has not yet been evaluated by NICE or the Surrey and Sussex Prescribing Clinical Network (PCN). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug / device. This drug is currently not on the PCN workplan. The PCN will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Please contact your local CCG Medicines Management team formulary pharmacist or chief pharmacist at your acute trust, if you wish to make a submission.

Green GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Local prescribing guidelines or NICE guidance may apply These are drugs that can be initiated and/or continued in primary, secondary or tertiary care.

To address concerns around the use of unlicensed dermatology specials and help to optimise quality of care, adherence to the revised British Association of Dermatologists (BAD) list of preferred Specials (2014) is encouraged. However, a licensed product should be used wherever possible.

The British Association of Dermatologists updated their guide for the use of unlicensed dermatology specials in 2018 - the resource can be found below

This drug / device falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care. Treatment should remain with the specialist (RED) hospital only drug. GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

NOTE - Terrosa and Movymia are biosimilars. It is therefore necessary to prescribe teriparatide by brand to ensure that the patient receives the intended product.

This drug / device falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care. Treatment should remain with the specialist (RED) hospital only drug.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.

This drug falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.

Clinicians / specialists within the Acute setting should only prescribe in line with their Trust formulary / pharmacy advice.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication

Not recommended in NICE TA223 (May 2011)

Not recommended by NICE TA223 (May 2011)

Not recommended by NICE TA223 (May 2011)

A pathway has been agreed for the use of home nebulised therapy in specific cohorts of patients. The nebuliser and ongoing consumables are supplied direct to the patients home by Philips Respironics.